SYK Earnings
Upcoming earnings date and last 8 quarters of EPS surprise.
Next Earnings
EPS Surprise — Last 8 Quarters
Quarterly Detail
| Quarter | Report Date | Est EPS | Actual EPS | Surprise % | Result |
|---|---|---|---|---|---|
| Q1 2026 | Apr 30, 2026 | 2.98 | 2.60 | -12.86% | Miss |
| Q4 2025 | Jan 29, 2026 | 4.40 | 4.47 | +1.70% | Beat |
| Q3 2025 | Oct 30, 2025 | 2.56 | 2.22 | -13.15% | Miss |
| Q2 2025 | Jul 31, 2025 | 3.07 | 3.13 | +1.95% | Beat |
| Q1 2025 | May 1, 2025 | 2.28 | 1.69 | -25.83% | Miss |
| Q4 2024 | Jan 28, 2025 | 3.87 | 4.01 | +3.49% | Beat |
| Q3 2024 | Oct 29, 2024 | 2.77 | 2.87 | +3.49% | Beat |
| Q2 2024 | Jul 30, 2024 | 2.79 | 2.81 | +0.68% | Inline |
Recent Guidance Mentions (8-K)
- Apr 30, 2026 · 8-K
quickly from the cyber incident and continue delivering for our customers and their patients,” said Kevin A. Lobo, Chair and CEO. “We remain committed to meeting our full year guidance for organic sales growth and adjusted earnings per share as our underlying business momentum remains strong.
View 8-K filing → - Apr 30, 2026 · 8-K
5% in the quarter. Adjusted net earnings per diluted share (1) of $2.60 decreased 8.5% in the quarter. 2026 Outlook We are maintaining our full year 2026 guidance of organic net sales growth (2) in the range of 8.
View 8-K filing → - Apr 30, 2026 · 8-K
0% to 9.5% and adjusted net earnings per diluted share (2) in the range of $14.90 to $15.10. Our sales guidance includes a modestly positive pricing impact. Additionally, foreign exchange is expected to have a slightly favorable impact on both sales and adjusted net earnings per diluted
View 8-K filing →
Data updated May 25, 2026 · source: Yahoo Finance via yfinance